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Seizures after single-agent overdose with pharmaceutical drugs: Analysis of 
cases reported to a poison centre 
Abstract 
Context. Seizures during intoxications with pharmaceuticals are a well-known complication. 
However, only a few studies report on drugs commonly involved and calculate the seizure 
potential of these drugs. Objectives. To identify the pharmaceutical drugs most commonly 
associated with seizures after single-agent overdose, the seizure potential of these 
pharmaceuticals, the age-distribution of the cases with seizures and the ingested doses. 
Methods. A retrospective review of acute single-agent exposures to pharmaceuticals reported to 
the Swiss Toxicological Information Centre (STIC) between January 1997 and December 2010 
was conducted. Exposures which resulted in at least one seizure were identified. The seizure 
potential of a pharmaceutical was calculated by dividing the number of cases with seizures by 
the number of all cases recorded with that pharmaceutical. Data were analyzed by descriptive 
statistics. Results. We identified 15 441 single-agent exposures. Seizures occurred in 313 
cases. The most prevalent pharmaceuticals were mefenamic acid (51 of the 313 cases), 
citalopram (34), trimipramine (27), venlafaxine (23), tramadol (15), diphenhydramine (14), 
amitriptyline (12), carbamazepine (11), maprotiline (10) and quetiapine (10). Antidepressants 
were involved in 136 cases. Drugs with a high seizure potential were bupropion (31.6%, seizures 
in 6 of 19 cases, 95% CI 15.4-50.0%), maprotiline (17.5%, 10/57, 95% CI 9.8-29.4%), 
venlafaxine (13.7%, 23/168, 95% CI 9.3-19.7%), citalopram (13.1%, 34/259, 95% CI 9.5-17.8%) 
and mefenamic acid (10.9%, 51/470, 95% CI 8.4-14.0%). In adolescents (15-19y/o) 23.9% (95% 
CI 17.6-31.7%) of the cases involving mefenamic acid resulted in seizures, but only 5.7% (95% 
CI 3.3-9.7%) in adults (≥20y/o) (p<0.001). For citalopram these numbers were 22.0% (95% CI 
12.8-35.2%) and 10.9% (95% CI 7.1-16.4%), respectively (p=0.058). The probability of seizures 
with mefenamic acid, citalopram, trimipramine and venlafaxine increased as the ingested dose 
increased. Conclusions. Antidepressants were frequently associated with seizures in overdose, 
but other pharmaceuticals, as mefenamic acid, were also associated with seizures in a 
considerable number of cases. Bupropion was the pharmaceutical with the highest seizure 
potential even if overdose with bupropion was uncommon in our sample. Adolescents might be 
more susceptible to seizures after mefenamic acid overdose than adults. 
Introduction 
Drug-related seizures account for 1.7 to 14% of all cases with acute symptomatic seizures.1-3 In 
a study from the California Poison Control System the rate of complications associated with 
drug-induced seizures was 60%.4 Complications as defined by the authors were a prolonged 
hospital stay, endotracheal intubation, status epilepticus, anoxic brain injury or death. Despite 
these facts epidemiologic data are rare and only a few studies address the problem of overdose-
induced seizures.5 In four studies the incidence rates of seizures after poisoning are reported to 
be between 1.3 and 5.2%.6-9 Five studies analyze the substances involved in poisoning-induced 
seizures.4,6,9-11 In all of them antidepressants were among the most frequent drugs and rates 
between 28.8 and 42.4% are reported. In four of the studies bupropion was the most prevalent 
pharmaceutical reported to cause seizures with rates between 14.9 and 23% of all cases.4,6,9,10 
The studies published so far include cases with single-agent exposures and mixed-ingestions. 
Coingestants are reported in 18.4-42% of the cases.4,6,10,11 
The aim of this study was to further the understanding of drug-induced seizures. We examined 
which pharmaceutical exposures are commonly associated with overdose-induced seizures and 
the potential of these pharmaceuticals to cause seizures. Furthermore we calculated the 
percentage of cases with seizures for different age groups and compared the rates of 
adolescents (15-19 years of age) and adults (≥20 years of age). To the best of our knowledge, 
there are no studies that describe these aspects in single-agent overdoses with 
pharmaceuticals. 
 
Methods 
Data collection 
The Swiss Toxicological Information Centre (STIC) provides medical advice concerning 
poisonings to the general public and to health professionals on a 24/7 basis. 
All calls to the STIC are recorded in an in-house database system. Collected data include age, 
weight and sex of the patient, circumstances of poisoning, ingested dose, clinical effects, 
temporal course of the poisoning, results of drug screening and laboratory analysis, clinical 
parameters, decontamination and treatment measures, antidotes given and medical 
complications. 
Study design 
The study was conducted as a retrospective single-centre review of consecutive single-agent 
overdoses with pharmaceutical drugs reported to the STIC between January 1, 1997 and 
December 31, 2010.  
Inclusion criteria 
We included all acute human single-agent overdoses with a pharmaceutical drug intended for 
human use. Furthermore a written feedback by a physician, providing sufficient data about 
clinical effects and evolution, had to be available. Among all single-agent overdoses we 
identified cases with occurrence of seizures by searching the data files for key words as 
epileptic, seizures or convulsions. 
Only cases with a confirmed or likely causal relationship between exposure and clinical effects 
were considered. Causality is determined by the following criteria: Cases with a likely causality 
are defined as having a clear temporal relationship between ingestion and clinical effects, 
absence of other reported drugs or absence of diseases which could explain the clinical effects 
and presence of symptoms which are described for the substance or are plausible from a 
pharmacodynamic point of view. Cases which fulfill the above mentioned criteria and have in 
addition an analytical detection (qualitative or quantitative) of the substance in a body fluid are 
defined as confirmed. Causality of asymptomatic cases without analysis of body fluids cannot be 
classified according to the above mentioned criteria. We included these cases according to the 
reported ingested substance.  
Ethics approval 
Ethics approval was not required due to the nature of the study design according to the 
regulations of the Cantonal Ethics Committee Zürich, Switzerland. 
Data analysis 
Confidence intervals (CI) of seizure rates were estimated using the technique described by 
Wilson12 as recommended in the applied statistical literature.13,14 Statistical tests of binomial 
coefficients were done using Fisher’s exact test, those comparing dose samples by the non-
parametric Wilcoxon-Mann-Whitney rank-sum test. All data evaluations were performed using 
the statistics and graphics software R.15 P-values <0.05 were considered statistically significant. 
The seizure rates in different age groups were calculated by dividing the number of reported 
cases associated with seizures in an age group by the number of all cases in the same age 
group. 
The seizure potential of a pharmaceutical was calculated by dividing the number of cases 
associated with seizures by the number of all cases recorded with that drug. 
 
Results 
The STIC answered a mean of 31 927 calls per year (range 29 506-34 283) during the study 
period. The referral population was about 7.1 million people at the beginning and about 7.8 
million people at the end of the study period.  
Over the 14 year study period 15 441 cases met the inclusion criteria. The patients were 
between 1 day and 98 years old (Table 1). There were 65.0% female and 32.1% male patients. 
Gender was not reported in 2.9% of the cases. Cases with accidental exposure (34.4%), 
intentional exposure (64.3%) and exposure by other reasons (1.3%) were recorded. Intentional 
exposures were mostly suicidal or abusive, exposure by other reasons include iatrogenic 
exposures or exposures with unknown reason. Analytical confirmation (quantitative or 
qualitative) was available in 9.2% of the cases.  
At least one seizure was recorded in 313 of the cases. The patients were between 1 and 90 
years old (Table 1). There were 70.0% female and 29.7% male patients. Gender was not 
reported in 0.3% of the cases with seizures. Cases with accidental exposure (13.4%), intentional 
exposure (85.0%) and exposure by other reasons (1.6%) were recorded. Analytical confirmation 
(quantitative or qualitative) was available in 15.3% of the cases with seizures. 
In the 313 cases with seizures 61 different pharmaceutical drugs were involved. Nineteen drugs 
were associated with three or more cases with seizures (Figure 1). The most prevalent drug was 
mefenamic acid (51 cases, 16.3%), followed by citalopram (34 cases, 10.9%), trimipramine (27 
cases, 8.6%), venlafaxine (23 cases, 7.3%), tramadol (15 cases, 4.8%), diphenhydramine (14 
cases, 4.5%), amitriptyline (12 cases, 3.8%), carbamazepine (11 cases, 3.5%), maprotiline (10 
cases, 3.2%), quetiapine (10 cases, 3.2%), fluoxetine (9 cases, 2.9%), dextromethorphan (8 
cases, 2.6%), chlorprothixene (8 cases, 2.6%), bupropion (6 cases, 1.9%), tolperisone (5 cases, 
1.6%), clozapine (4 cases, 1.3%), clomipramine (4 cases, 1.3%), olanzapine (3 cases, 1.0%) 
and methadone (3 cases, 1.0%). These 19 pharmaceuticals were responsible for 82% (257/313) 
of all cases. The seizures in the remaining 56 cases were associated with 42 further drugs with 
14 pharmaceuticals associated with two cases with seizures each (bupivacaine, clotiapine, 
codeine, dibenzepin, doxepin, fluvoxamine, ioxaglic acid, isoniazid, lamotrigine, lidocaine, 
opipramol, phenobarbital, propranolol and verapamil) and a wide variety of 28 pharmaceuticals 
associated with one case with seizures each (see online supplementary data). Antidepressants 
(AD) were associated with 136 cases with seizures (43.5%), antipsychotics with 30 (9.6%) and 
antiepileptics with 17 (5.4%) cases (Table 2). 
The highest seizure potential was found with bupropion. Seizures were recorded in 31.6% (6/19 
cases; 95% CI 15.4-54.0%). It was followed by maprotiline 17.5% (10/57 cases; 95% CI 9.8-
29.4%), venlafaxine 13.7% (23/168 cases; 95% CI 9.3-19.7%), citalopram 13.1% (34/259 cases; 
95% CI 9.5-17.8%) and mefenamic acid 10.9% (51/470 cases; 95% CI 8.4-14.0%) (Figure 2). 
The 313 cases with seizures result in a seizure rate of 2.0% (313/15 441). For seizure rates in 
the different age groups see Table 1. The difference between the rate of 4.3% in adolescents 
(15-19y/o) and the rate of 2.3% in adults (≥20y/o) is statistically significant (p<0.001). Regarding 
this age-difference we calculated the rates for the four pharmaceuticals with most seizure cases. 
For mefenamic acid the difference of the rates between adolescents 23.9% (95% CI 17.6-
31.7%) and adults 5.7% (95% CI 3.3-9.7%) was significant (p<0.001).. For citalopram the 
seizure rates for adolescents and adults were 22.0% (95% CI 12.8-35.2%) and 10.9% (95% CI 
7.1-16.4%), respectively (p=0.058). No age-difference could be found for trimipramine (p=0.73) 
and venlafaxine (p=0.48). If we exclude the 51 cases with mefenamic acid from the 313 cases, 
the difference in rates between adolescents and adults was no more significant (p=0.17). The 
seizure rates for adolescents and adults were 2.8% (95% CI 2.1-3.7%) and 2.2% (95% CI 1.9-
2.6%), respectively. 
To exclude a dose-effect causing the age-difference in mefenamic acid and citalopram cases, 
we calculated the medians of the reported ingested doses for the two drugs. There was no 
significant difference of the doses between adolescents and adults. For mefenamic acid the 
median doses were 8.5g (131.1mg/kg) in adolescents and 10.0g (130.3mg/kg) in adults (p=0.39 
for dose in g, p=0.74 for dose in mg/kg). Dose as reported by the patient or a caregiver was 
available in 92.2% of the cases with seizures and in 84.7% of all cases. The median of the 
ingested doses for citalopram were 1.0g (15.6mg/kg) and 1.3g (19.7mg/kg), respectively (p=0.35 
and 0.70). Dose as reported by the patient or a caregiver was available in 85.3% of the cases 
with seizures and in 86% of all cases. 
Table 3 shows the ranges and medians of the ingested doses of the four pharmaceuticals most 
commonly associated with seizures. The probability of seizures increased as the dose increased 
and the difference between the medians of the ingested doses in cases with and without 
seizures was significant with p<0.001 for each of the four agents. 
 
Discussion 
Drugs involved 
In the literature only case series are reported which include cases with co-ingestants, no studies 
were found which analyze only single-agent overdoses associated with drug-induced seizures. 
In case series the authors assigned the drug with an already described seizure risk to be the 
likely cause of the convulsions in cases with multi-drug exposures.4,6,10,11 This could bias the 
results in cases with ingestion of more than one substance described to cause seizures or in 
cases with new substances not yet known to cause seizures which are co-ingested with 
substances with a known seizure risk. The fact that we only considered single-agent exposures 
strengthens the causal association between the seizures and the ingested pharmaceutical. 
As in the present study, all studies so far found high rates of seizures associated with 
antidepressants (28.8-42.4%).4,6,9-11 Antidepressants are known to have a considerable potential 
to cause seizures in overdose, some agents having a seizure rate of >10%.16  
However, the pharmaceutical most often associated with drug-induced seizures in the present 
study was mefenamic acid. This non-steroidal anti-inflammatory drug (NSAID) is widely available 
as an analgesic in Switzerland and a few other countries, but not in the USA and therefore was 
probably not reported in the aforementioned studies. The other pharmaceuticals which were 
associated with seizures in more than 5% of the cases in our study are also described in the 
literature. Thundiyil et al4 found the seizure rate for cases with citalopram/escitalopram overdose 
to be 8.3% and the one for venlafaxine 1.7%. In a another study by Thundiyil et al10 the seizure 
rate for venlafaxine was 6%. The proportion of trimipramine-induced seizure is not described in 
the literature, but in three studies rates of seizures induced by tricyclic antidepressants were 
between 1.7 and 24.6%.4,10,11 
Seizure potential 
A high number of cases with seizures associated with a particular drug could mean that this drug 
has a high seizure potential or that it is more often involved in overdose, or both. The studies 
which analyzed cases with seizures reported so far do not report data about the corresponding 
cases with the same substance without occurrence of seizures during the time interval studied, 
therefore seizure potentials cannot be calculated.4,6-11 However, there are some studies 
analyzing clinical effects in overdose of single substances or of drug classes that mention 
seizure potentials.17-21 In our study the highest seizures potential was reached by bupropion. 
Bupropion overdose was a rare event with only 19 exposures, but these intoxications were 
associated with seizures in six of the cases. Bupropion is known to frequently cause seizures in 
overdose18,22 and it was the single drug causing most seizures in three studies.4,9,10 Despite the 
small number of cases our analysis confirms the high potential of bupropion to cause seizures in 
overdose. For maprotiline, venlafaxine, citalopram and mefenamic acid we found a seizure 
potential of more than 10%. This considerable risk of seizures in overdose is described in the 
literature. Seizures occurred in more than 10% of acute maprotiline intoxications,16,20,23 in 4-
13.7% of venlafaxine intoxications,19,20,24-27 in 5.8-15.9% of citalopram intoxications20,21,28-30 and 
in 14-39.3% of mefenamic acid intoxications.17,31-33 
Seizure rates and age distribution 
In the literature rates of seizures associated with intoxications are reported in four case series.6-9 
In a recent study with cases reported to a toxico-surveillance system seizures occurred in 4.7% 
of the patients younger than 18 years and in 4.5% of the adult patients.6 In a retrospective 
review 1.6% of 1561 children (3-172 months) admitted for intoxication developed seizures.7 In 
another retrospective review seizures occurred in 1.3% of 3687 children (0-18 years) admitted to 
a pediatric toxicology department.8 In a case series with adults 5.2% of 2340 patients admitted 
to a poisoning treatment centre had seizures.9 In all four case series also multiple-agent 
exposures were analyzed and substances other than pharmaceutical drugs were included. In 
our study, which is one of the largest to date describing seizure rates in cases with overdose, we 
found very low seizure rates of 0.4 and 0.6% in children of 0-4 and 5-9 years of age, 
respectively. In poisonings, seizure rates in children are expected to be lower than in adults 
since intoxications in children less than 10 years of age are almost exclusively accidental and 
smaller doses are ingested than in intentional poisonings. The seizure rate of all patients from 0-
19 years of age was 1.7% and is comparable to the data given by Citak (1.6%)7 and Nitescu 
(1.3%)8, but lower than the one reported by Finkelstein (4.7%).6 The seizure rate of 2.3% we 
found in adults (≥20 y/o) is lower than the rates reported by Kirschner (5.2%)9 and Finkelstein 
(4.5%).6 The differences might be due to our strict inclusion criteria (only single-agent 
exposures, only pharmaceutical drugs), but could also be a consequence of other reasons, as 
ingestion of different amounts or substances or a different patient collective. 
One interesting result of our study is the higher seizure rate in adolescents (15-19 y/o) compared 
to adults (≥20y/o), which is almost exclusively due to the cases with mefenamic acid. An age-
dependency of seizures in mefenamic acid overdose has already been described earlier. In a 
case series seizures were seen in 22.3% of the cases in 16-20 year olds, but only in 7.1% of 
patients older than 20 years of age.33 Also in the cases with citalopram adolescents had more 
seizures than adults, but this difference was statistically not significant. The most obvious reason 
for an apparent age-dependency of seizures would be that adolescents could have ingested 
higher doses, since a dose-dependency for occurrence of seizures is well described.22,30,34 
However, we could not find a significant difference of the medians of the ingested doses of 
mefenamic acid or citalopram in the two groups. Furthermore, adolescents could genuinely be 
more susceptible to seizures. It is known that during adolescence important changes take place 
in the brain, such as remodeling of synaptic connections.35 There is also some evidence from 
animal models that during adolescence susceptibility to seizures is increased36,37 and reported 
annual incidence rates of epilepsy are higher in patients of 10-19 years of age than in adults.38  
Ingested dose and probability of seizures 
Dose-dependency of occurrence of seizures is well-known in cases of drug overdose34 and is 
reported in the literature for mefenamic acid,17,32,33 citalopram, 21,28,29 trimipramine 39 and 
venlafaxine.19 The results in the literature and of our study support the mechanistic view of the 
pathophysiology of seizures in overdose which are thought to be provoked by overexcitation of 
the brain by different pathways in a dose-dependent manner.5,40 
Limitations 
This study has several limitations due to the inherent nature of poison centre data.41 The study 
has a retrospective design and certain information might be missing in some of the cases. Some 
clinical effects might be underreported, but seizures are an obvious effect and recording is quite 
probable. Reporting to poison centres is voluntary and the seizure rate could be overestimated 
since the poison centre might not be called for advice in cases with minor ingestions or in cases 
with substances the treating physician is familiar with. The ingested substances are based 
mainly on reports of the patient or caregivers in cases involving children. Analytical confirmation 
was available only in a minority of the cases, so we cannot exclude definitely that other 
substances have been co-ingested. We did not consider factors as dose, age or comorbidities in 
calculating the seizure potential which could influence the result. So it cannot be excluded that 
pharmaceuticals with a high seizure potential were taken in a higher relative dose or by a 
different age group than drugs with a lower seizure potential. But the drugs we found to have a 
high seizure potential are described in the literature as frequently causing seizures in overdose. 
Our results can only partly be generalized as the frequency of use of pharmaceutical drugs may 
vary considerably among different countries. Our strict inclusion/exclusion criteria with exclusion 
of multiple-agent exposures result in smaller case numbers. However, the inclusion of only 
single-agent exposures favors a correct interpretation of the results, seizures do not have to be 
assigned to one of the drugs ingested and interactions between different pharmaceuticals can 
be excluded.  
 
Conclusions 
Our study confirms that antidepressants play an important role in overdose-induced seizures, 
many substances with a high seizure potential are found in this drug class. But a variety of other 
pharmaceutical drugs, as mefenamic acid can also be frequently associated with seizures in 
overdose. The most frequent pharmaceuticals associated with seizures do not necessarily have 
the highest seizure potential. This was shown for bupropion, which has a very high seizure 
potential, but was only involved in 1.9% of the cases with seizures, in comparison to mefenamic 
acid, which was the most prevalent drug associated with seizures, but has a lower seizure 
potential than bupropion. Adolescents were more likely to develop seizures than adults with 
mefenamic acid. This finding deserves further consideration for other substances. The 
probability of seizures with mefenamic acid, citalopram, trimipramine and venlafaxine increased 
as the ingested dose increased. 
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 Age 
[years] 
All 
cases* 
All 
Cases 
[%] 
Cases 
with 
seizures* 
Cases 
with 
seizures 
[%] 
Seizure 
rate [%] 
95% Confidence 
interval 
Lower 
bound 
[%] 
Upper 
bound 
[%] 
0-4 3646 24.4 14 4.6 0.4 0.2 0.6 
5-9 359 2.4 2 0.7 0.6 0.2 2.0 
10-14 639 4.3 12 3.9 1.9 1.1 3.3 
15-19 1934 13.0 83 27.3 4.3 3.5 5.3 
20-99 8349 55.9 193 63.5 2.3 2.0 2.7 
0-99 14927 100.0 304 100.00 2.0 1.8 2.3 
 
Table 1 
 Drug Number of seizures Seizures in [%] of 
all seizures 
Antidepressants 136 43.5 
    TCAs 50 16.0 
    SSRIs 47 15.0 
    Venlafaxine 23 7.3 
    Maprotiline 10 3.2 
    Bupropion 6 1.9 
Antipsychotics 30 9.6 
    Quetiapine 10 3.2 
    Chlorprothixene 8 2.6 
    Clozapine 4 1.3 
    Olanzapine 3 1.0 
    Clotiapine 2 0.6 
    Flupentixol 1 0.3 
    Levomepromazine 1 0.3 
    Promazine 1 0.3 
Antiepileptics 17 5.4 
    Carbamazepine 11 3.5 
    Lamotrigine 2 0.6 
    Tiagabine 1 0.3 
    Oxcarbazepine 1 0.3 
    Valproic acid 1 0.3 
    Phenytoin 1 0.3 
 
Table 2 
 
Drug Cases Dose range [g] Median dose [g] 
Mefenamic acid all 0.1-45.0 6.0 
with seizures 4.5-36.0 8.5 
Citalopram all 0.01-4.0 0.4 
with seizures 0.28-2.4 1.1 
Trimipramine all 0.01-30.0 1.1 
with seizures 0.35-10.0 2.0 
Venlafaxine all 0.038-29.4 1.5 
with seizures 1.2-22.0 4.0 
 
Table 3 
Captions of tables 
Table 1. Age distribution of cases with and without seizures and seizure rates. 
*Precise age was not known in 514 of all cases and in 9 of the cases with seizures. 
Table 2. Seizure rates in different drug classes. The table indicates the absolute number of 
seizures and the percentage in relation to all 313 cases with seizures. TCAs=tricyclic 
antidepressants, SSRIs= selective serotonin reuptake inhibitors. 
Table 3. Dose ranges and medians of ingested doses of the pharmaceuticals associated with 
more than 20 cases with seizures. 
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 Captions of figures 
Figure 1. Pharmaceutical drugs associated with ≥ 3 cases with seizures. Lines correspond to 
95% confidence intervals. For all involved pharmaceuticals see online supplementary data. 
Figure 2. Seizure potential of pharmaceuticals in overdose. Lines correspond to 95% confidence 
intervals.  
Pharmaceuticals Number of all 
cases with a 
pharma-
ceutical 
Number of 
cases with 
seizures 
Seizures in 
[%] of all 313 
cases with 
seizures (see 
also Figure 1) 
95% Confidence 
interval 
Lower 
bound 
[%] 
Upper 
bound 
[%] 
Mefenamic acid 470 51 16.3 12.6 20.8 
Citalopram 259 34 10.9 7.9 14.8 
Trimipramine 336 27 8.6 6.0 12.3 
Venlafaxine 168 23 7.3 4.9 10.8 
Tramadol 157 15 4.8 2.9 7.8 
Diphenhydramine 429 14 4.5 2.7 7.4 
Amitriptyline 220 12 3.8 2.2 6.6 
Carbamazepine 163 11 3.5 2.0 6.2 
Maprotiline 57 10 3.2 1.7 5.8 
Quetiapine 256 10 3.2 1.7 5.8 
Fluoxetine 118 9 2.9 1.5 5.4 
Chlorprothixene 245 8 2.6 1.3 5.0 
Dextromethorphan 586 8 2.6 1.3 5.0 
Bupropion 19 6 1.9 0.9 4.1 
Tolperisone 54 5 1.6 0.7 3.7 
Clomipramine 50 4 1.3 0.5 3.2 
Clozapine 164 4 1.3 0.5 3.2 
Methadone 162 3 1.0 0.3 2.8 
Olanzapine 156 3 1.0 0.3 2.8 
Bupivacaine 4 2 0.6 0.2 2.3 
Clotiapine  81 2 0.6 0.2 2.3 
Codeine 70 2 0.6 0.2 2.3 
Dibenzepin 3 2 0.6 0.2 2.3 
Doxepin 22 2 0.6 0.2 2.3 
Fluvoxamine 42 2 0.6 0.2 2.3 
Ioxaglic acid 2 2 0.6 0.2 2.3 
Isoniazid 8 2 0.6 0.2 2.3 
Lamotrigine 55 2 0.6 0.2 2.3 
Lidocaine 13 2 0.6 0.2 2.3 
Opipramol 27 2 0.6 0.2 2.3 
Phenobarbital 88 2 0.6 0.2 2.3 
Propranolol 58 2 0.6 0.2 2.3 
Verapamil 33 2 0.6 0.2 2.3 
Amine compounds 1 1 0.3 0 1.8 
Aminophylline 4 1 0.3 0 1.8 
Atropine 35 1 0.3 0 1.8 
Barium 4 1 0.3 0 1.8 
Biperiden 28 1 0.3 0 1.8 
Chloral hydrate 59 1 0.3 0 1.8 
Cyclopentolate 3 1 0.3 0 1.8 
Dapsone 4 1 0.3 0 1.8 
Dosulepin 6 1 0.3 0 1.8 
Fluoride 11 1 0.3 0 1.8 
Flupentixol 43 1 0.3 0 1.8 
Glibenclamide 6 1 0.3 0 1.8 
Ketamine 5 1 0.3 0 1.8 
Levomepromazine 146 1 0.3 0 1.8 
Methaqualone 16 1 0.3 0 1.8 
Metoclopramide 57 1 0.3 0 1.8 
Midazolam1 126 1 0.3 0 1.8 
Morphine 65 1 0.3 0 1.8 
Oxcarbazepine 12 1 0.3 0 1.8 
Paroxetine 115 1 0.3 0 1.8 
Phenytoin 28 1 0.3 0 1.8 
Promazine 104 1 0.3 0 1.8 
Propafenone 3 1 0.3 0 1.8 
Sertraline 150 1 0.3 0 1.8 
Thiopental 1 1 0.3 0 1.8 
Tiagabine 1 1 0.3 0 1.8 
Valproic acid 120 1 0.3 0 1.8 
Zolpidem2 630 1 0.3 0 1.8 
 
Table Online supplementary data 
 Captions online supplementary data 
Table. Pharmaceutical drugs associated with seizures. 1Focal twitching after application of 
flumazenil. 2Seizure reported, but not witnessed by a medical professional  
 
